Sino Biopharmaceutical's Total Assets for the quarter that ended in Jun. 2023 was $9,166 Mil.
Warning Sign:
If a company builds assets at 33.6% a year, faster than its revenue growth rate of 9.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Sino Biopharmaceutical's average Total Assets Growth Rate was -5.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 37.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 33.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 26.90% per year.
During the past 13 years, Sino Biopharmaceutical's highest 3-Year average Total Assets Growth Rate was 52.70%. The lowest was 5.80%. And the median was 29.50%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sino Biopharmaceutical's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (OTCPK:SBMFF) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sino Biopharmaceutical's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sino Biopharmaceutical Total Assets Related Terms
Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.
Sino Biopharmaceutical (Sino Biopharmaceutical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBMFF has been successfully added to your 